Johnson & Johnson (NYSE:JNJ) Shares Sold by PFC Capital Group Inc.

PFC Capital Group Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 14.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 12,836 shares of the company’s stock after selling 2,175 shares during the period. Johnson & Johnson makes up 0.9% of PFC Capital Group Inc.’s investment portfolio, making the stock its 26th largest position. PFC Capital Group Inc.’s holdings in Johnson & Johnson were worth $1,856,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in JNJ. IFS Advisors LLC increased its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the fourth quarter worth about $32,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $38,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 1.3 %

Shares of JNJ stock opened at $165.89 on Tuesday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a 50-day simple moving average of $159.06 and a 200 day simple moving average of $156.07. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock has a market capitalization of $399.76 billion, a P/E ratio of 24.95, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the firm posted $2.29 EPS. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 2.99%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on JNJ shares. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Wells Fargo & Company dropped their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.